Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

6-9 November, 2018
Postillion Convention Center,
Amsterdam, Netherlands

Improve delivery and drive products to market through expert insight, new data and technology for oligonucleotide therapeutics

Accelerate your oligonucleotide therapeutics to market

R&D Strategies & Delivery
  • Stay on top of new techniques for improved delivery beyond the liver
  • Discover the latest design approaches to produce stereo defined oligonucleotides
  • Explore next generation R&D strategies and innovative chemistries
Manufacturing & Scale Up
  • Delve into strategies to reduce cost of goods and improve manufacturing efficiency
  • Master process development and scale up of complex oligonucleotide therapeutics
  • Discover how enzyme catalysed assembly and liquid phase synthesis can be applied to large scale production
Preclinical & Clinical
  • What are the most exciting oligonucleotides advancing through the clinic?
  • Get top tips learnt from preclinical and clinical development
  • Examine approaches to extend oligonucleotide products to mass markets
CMC & Analytical Methods
  • Uncover analytical methods to identify and characterise oligonucleotide impurities
  • Learn how industry are developing CMC control strategies
  • Understand how mass spectrometry can be applied for product characterisation
mRNA & CRISPR
  • Hear the latest preclinical and clinical developments
  • Overcome the delivery challenges for mRNA and CRISPR therapeutics
  • Tackle analytical method development, scale up and large-scale manufacturing
Keynotes
  • RNAi Therapeutics Delivered: From Principles to Patients
    • Muthiah (Mano) Manoharan, Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Successes in High Unmet Need Diseases
    • Steve Hughes, Ionis Pharmaceuticals

New topics and industry case studies for 2018 focused on:

  • Messenger RNA Therapeutics
  • CRISPR-Cas9 and Applications of Genome Editing
  • Risk-based Approaches to CMC Development of Therapeutics Oligonucleotides
  • Opportunities for Extending to Larger Disease Populations
  • Stereochemical Control of Antisense Oligonucleotides Enhances Target Efficacy
  • Mechanisms of Action and Quantification of Biodistribution of Oligonucleotides
  • Alternative Manufacturing Technologies to Reduce Cost of Goods in Oligonucleotide Manufacturing: Application of Enzymatic Manufacturing
  • Late Stage Drug Product Development and Drug Product Manufacturing
  • Nonclinical Case Studies in Oligonucleotide Development
  • Regulatory Authority Expectations

Gain the Science, Technologies and Contacts You Need to Accelerate Peptide Therapeutics to Market

300+
OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES
40+
CASE STUDIES AND NEW DATA PRESENTATIONS
30+
LEADING EXHIBITORS

Thank you to our EuroTIDES 2018 Scientific Advisory Board

  • Muthiah (Mano) Manoharan, Senior VP, Drug Discovery, Alnylam Pharmaceuticals, Inc, USA
  • Yogesh Sanghvi, President, Rasayan, USA
  • Troels Koch, VP & Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen A/S, Denmark
  • Thomas Rupp, Owner, Thomas Rupp Consulting, Germany
  • Professor Cy Stein, Department of Medical Oncology and Experimental Therapeutics, City of Hope Medical Center, USA
  • Mike Gait, MRC Programme Leader, MRC Laboratory of Molecular Biology, UK
  • Dmitry Samarsky, Oligonucleotide (RNAi) Technology and Therapeutics, Experienced Executive and Industry Expert

PARTNERING OPPORTUNITIES FOR EUROTIDES 2018


Highlight your company's expertise to 300+ scientists and key decision makers working across peptide & oligonucleotide development.  A wide variety of options are available to accommodate your company's goals and budget.